Cláudia Marchetti - Concepedia

Author

Cláudia Marchetti

Also Known As

C Marchetti, C. Marchetti, CLAUDIA MARCHETTI, Camille Marchetti, Cicilia MARCHETTI, Claudia Marchetti, Cláudia Marchetti, M Lauretta, Marchetti, Claudia, PALAIA, INNOCENZA

335

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

Sapienza University of Rome Agostino Gemelli University Polyclinic Policlinico Umberto I Università Cattolica del Sacro Cuore Istituti di Ricovero e Cura a Carattere Scientifico

About

Cláudia Marchetti is an author at Sapienza University of Rome specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	30	1.6K
2	Public Health	4	4	73
3	Cell Biology	2	2	159
4	Health Sciences	1	1	20
5	Endocrinology	1	1	27

Cláudia Marchetti

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, The Lancet Oncology Advanced Ovarian CancerMedicineMetronomic TherapyGynecologyWeek Versus	2014	386
PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track? Maria Luisa Gasparri, Erlisa Bardhi, Ilary Ruscito, Geburtshilfe und Frauenheilkunde Mtor ProteinsGynecologyCancer BiologyTumor BiologyOvarian Cancer	2017	132
Second surgery for recurrent endometriomas is more harmful to healthy ovarian tissue and ovarian reserve than first surgery Ludovico Muzii, Chiara Achilli, Francesca Lecce, Fertility and Sterility	2015	121
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, Gynecologic Oncology MedicineCancer ManagementGynecologyMaintenance TherapyBrca 1–2	2019	103
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study Marco Petrillo, Cláudia Marchetti, R. De Leo, American Journal of Obstetrics and Gynecology Cancer RiskMedicineGynecologyPathologyBrca Mutational Status	2017	92
Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery Pierluigi Benedetti Panici, Violante Di Donato, Margherita Fischetti, Gynecologic Oncology Gynecologic SurgerySurgical OncologyGynecological SurgeryAdvanced Ovarian CancerUpper Abdominal Surgery	2015	90
Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case–control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis Nadia Recine, Ettore Palma, Lavinia Domenici, Archives of Gynecology and Obstetrics Medical MicrobiologyProbioticVulvar DiseasesMicrobial DiseaseMedicine	2015	84
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma Pierluigi Benedetti Panici, S. Basile, Maria Giovanna Salerno, American Journal of Obstetrics and Gynecology Randomized Clinical TrialMedicineClinical EndpointEpidemiology Of CancerGynecology	2013	81
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1 Enrica Vescarelli, Giulia Gerini, Francesca Megiorni, Journal of Experimental & Clinical Cancer Research	2020	75
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression Chiara Napoletano, Filippo Bellati, Rachele Landi, Journal of Cellular and Molecular Medicine	2009	72

Page 1